{"altmetric_id": 91253214, "counts": {"readers": {"mendeley": 0, "citeulike": 0, "connotea": 0}, "total": {"posts_count": 14}, "twitter": {"unique_users_count": 11, "posts_count": 12}, "blogs": {"unique_users_count": 2, "unique_users": [80632, 60332], "posts_count": 2}}, "citation": {"altmetric_jid": "532721422a83ee84788b4567", "authors": ["Fagre, Anna C.", "Manhard, John", "Adams, Rachel", "Eckley, Miles", "Zhan, Shijun", "Lewis, Juliette", "Rocha, Savannah M.", "Woods, Catherine", "Kuo, Karina", "Liao, Wuxiang", "Li, Lin", "Corper, Adam", "Challa, Dilip", "Mount, Emily", "Tumanut, Christine", "Tjalkens, Ronald B.", "Aboelleil, Tawfik", "Fan, Xiaomin", "Schountz, Tony"], "doi": "10.1101/2020.09.25.313601", "first_seen_on": "2020-09-25T23:37:19+00:00", "issns": [], "journal": "bioRxiv", "last_mentioned_on": 1613088000, "links": ["https://www.biorxiv.org/content/10.1101/2020.09.25.313601v1", "http://dx.doi.org/10.1101/2020.09.25.313601", "https://www.researchgate.net/publication/344415987_A_potent_SARS-CoV-2_neutralizing_human_monoclonal_antibody_that_reduces_viral_burden_and_disease_severity_in_Syrian_hamsters", "https://doi.org/10.1101/2020.09.25.313601"], "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/09/25/2020.09.25.313601.full.pdf", "pmid": "33024962", "publisher": "Cold Spring Harbor Laboratory", "title": "A potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters", "type": "article"}, "altmetric_score": {"score": 18.26, "score_history": {"1y": 18.26, "6m": 5.08, "3m": 0, "1m": 0, "1w": 0, "6d": 0, "5d": 0, "4d": 0, "3d": 0, "2d": 0, "1d": 0, "at": 18.26}, "context_for_score": {"all": {"total_number_of_other_articles": 17704521, "mean": 9.4414773599323, "rank": 1261697, "this_scored_higher_than_pct": 92, "this_scored_higher_than": 16447358, "rank_type": "exact", "sample_size": 17704521, "percentile": 92}, "similar_age_3m": {"total_number_of_other_articles": 317202, "mean": 17.464685525311, "rank": 37819, "this_scored_higher_than_pct": 88, "this_scored_higher_than": 279387, "rank_type": "exact", "sample_size": 317202, "percentile": 88}, "this_journal": {"total_number_of_other_articles": 120900, "mean": 13.89449139785, "rank": 19501, "this_scored_higher_than_pct": 83, "this_scored_higher_than": 101400, "rank_type": "exact", "sample_size": 120900, "percentile": 83}, "similar_age_this_journal_3m": {"total_number_of_other_articles": 9221, "mean": 13.499387918881, "rank": 1426, "this_scored_higher_than_pct": 84, "this_scored_higher_than": 7796, "rank_type": "exact", "sample_size": 9221, "percentile": 84}}}, "demographics": {"poster_types": {"member_of_the_public": 11}, "users": {"twitter": {"cohorts": {"Members of the public": 11}}}, "geo": {"twitter": {"US": 4, "IT": 1, "PK": 1}}}, "posts": {"twitter": [{"license": "gnip", "citation_ids": [91253214], "author": {"tweeter_id": "1949132852"}, "tweet_id": "1309633031255339009"}, {"license": "gnip", "citation_ids": [91253214], "author": {"tweeter_id": "748908558066982916"}, "tweet_id": "1309633032421244928"}, {"license": "gnip", "citation_ids": [91253214], "author": {"tweeter_id": "1256280966101942273"}, "tweet_id": "1309765572503236609"}, {"license": "gnip", "citation_ids": [91253214], "author": {"tweeter_id": "1265336030833422337"}, "tweet_id": "1310628951216193536"}, {"license": "gnip", "citation_ids": [91253214], "author": {"tweeter_id": "254740822"}, "tweet_id": "1310946345923076101"}, {"license": "gnip", "citation_ids": [91253214], "author": {"tweeter_id": "1053359667995463682"}, "tweet_id": "1311566769400827904"}, {"license": "gnip", "citation_ids": [91253214], "author": {"tweeter_id": "303495844"}, "tweet_id": "1311567179624587264"}, {"license": "gnip", "citation_ids": [91253214], "author": {"tweeter_id": "463162523"}, "tweet_id": "1311567814545858560"}, {"license": "gnip", "citation_ids": [91253214], "author": {"tweeter_id": "3824923812"}, "tweet_id": "1311649078413946882"}, {"license": "gnip", "citation_ids": [91253214], "author": {"tweeter_id": "348694247"}, "tweet_id": "1311834948488237056"}, {"license": "gnip", "citation_ids": [91253214], "author": {"tweeter_id": "1244711417657376768"}, "tweet_id": "1312848788797689867"}, {"license": "gnip", "citation_ids": [91253214], "author": {"tweeter_id": "254740822"}, "tweet_id": "1326991203204616192"}], "blogs": [{"title": "A potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters.", "url": "https://clinowl.com/a-potent-sars-cov-2-neutralizing-human-monoclonal-antibody-that-reduces-viral-burden-and-disease-severity-in-syrian-hamsters/?utm_source=rss&utm_medium=rss&utm_campaign=a-potent-sars-cov-2-neutralizing-human-monoclonal-antibody-that-reduces-viral-burden-and-disease-severity-in-syrian-hamsters", "license": "public", "citation_ids": [91253214], "posted_on": "2020-10-06T23:00:00+00:00", "summary": "The emergence of COVID-19 has led to a pandemic that has caused millions of cases of disease, variable morbidity and hundreds of thousands of deaths. Currently, only remdesivir and dexamethasone [...]", "author": {"name": "Clinowl", "url": "https://clinowl.com/"}}, {"title": "Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection", "url": "https://www.cell.com/cell/fulltext/S0092-8674(21)00176-8?rss=yes", "license": "public", "citation_ids": [41390295, 102380038, 91253214, 936135, 1302275, 101728471, 7183900, 74953044, 61206619, 78976480, 100017458, 100017458], "posted_on": "2021-02-12T00:00:00+00:00", "summary": "Neutralizing human monoclonal antibodies (mAbs) against SARS-CoV-2 require Fc effector functions for optimal protection during post-exposure therapy, with intact mAbs reducing SARS-CoV-2 burden and lung disease in rodent models better than LALA-PG loss-of-", "author": {"name": "Cell", "url": "http://www.cell.com/cell/current", "description": "Cell RSS feed. For more than 30 years, top international researchers have relied on Cell to publish high impact papers that have come to form the foundation of contemporary life science research.  Founded by Benjamin Lewin (author of Genes), Cell remains at the forefront of exciting developments in biology, continually redefining the important areas of science with cutting edge papers. Published biweekly, Cell includes original research articles of exceptional significance in areas including molecular biology, biochemistry, cancer research, cell biology, developmental biology, genetics, immunology, microbiology, neurobiology, plant biology, structural biology and virology. Submitted articles are reviewed rapidly for both technical quality and general interest, and, if accepted, are published within eight weeks. Cell features topical minireview and review articles in which noted scientists discuss current progress in all areas of the life sciences. Cell also publishes commentaries, meeting reviews, letters to the editor, and book reviews, as well as Positions Available and listings of Conferences and Courses.Visit the Cell website to find out more -  http://www.cell.com."}}]}, "score": 18.26, "images": {"small": "https://badges.altmetric.com/?size=64&score=19&types=bttttttt", "medium": "https://badges.altmetric.com/?size=100&score=19&types=bttttttt", "large": "https://badges.altmetric.com/?size=180&score=19&types=bttttttt"}}